In fall 2026, the Advarra-facilitated Site-Sponsor Consortium will release a white paper on reducing redundant site training through competency-based, role-based, and reusable training models while aligning with international regulatory guidelines.
This is Part 3 of a three-part series on the site initiation visit (SIV) aspect of training: where redundancy appears, what should remain live and study-specific, and how a better model could separate common training from protocol-specific readiness.
Stop treating the SIV like one giant training container
Part 1 and part 2 of this series made two arguments:
- A large share of SIV training is redundant and trial-agnostic.
- The SIV should be protected for content that’s genuinely study-specific, high-risk, or operationally nuanced.
The logical next step is to redesign the training model.
A key problem is that different types of preparation are often collapsed into one event. A better model separates reusable site-readiness training, vendor system training, and sponsor/contract research organization (CRO)-led protocol discussion.
The current model asks one event to do everything
In many studies, the SIV is used to train sites on universal clinical research expectations, sponsor/CRO operating preferences, protocol science, eligibility, safety reporting, source documentation, trial file expectations, electronic data capture (EDC) entry, interactive response technology/randomization and trial supply management (IRT/RTSM) workflows, central lab portals, imaging uploads, electronic patient-reported outcomes (ePRO) devices, investigational product handling, and administrative readiness.
That’s too much for one event. More importantly, much of it doesn’t require an event at all.
Some content is reusable across studies. Some content is vendor-specific and better delivered asynchronously. Some content is truly protocol-specific and should be discussed live.
When these categories are combined into a single SIV deck, the result is often a long presentation that can make every topic feel equally important, even when the real risks are concentrated in a smaller set of study-specific issues.
In Part 1, we shared that the 16 SIV training decks we reviewed ranged from 75 pages to (a staggering) 381 pages. Decks of that length are simply not effective learning tools.
A three-layer model
A more practical approach is to divide SIV training into three layers.
Layer 1: Reusable, core site-readiness training
The first layer is reusable core training. This content is largely study-invariant and could be completed annually or at another reasonable interval, depending on role and organization.
A core module could include the following stable readiness topics:
- Good Clinical Practice (GCP) and International Council for Harmonization (ICH)-GCP principles
- Principal investigator (PI) oversight
- Staff delegation
- Informed consent principles
- Privacy and confidentiality
- Documentation of training and qualifications
- Source documentation
- Data integrity
- Basic safety reporting concepts
- Protocol deviation principles
- Corrective and preventive action (CAPA) and root cause analysis
- Monitoring expectations
- Audit readiness
These are important topics. But they do not need to be rebuilt into every SIV deck as if every qualified site is encountering them for the first time.
Layer 2: Vendor micro-modules
The second layer is vendor and platform training. This includes EDC, IRT/RTSM, ePRO/electronic clinical outcome assessments (eCOA), central lab portals, imaging portals, safety distribution systems, and other technology or vendor tools.
These tools are operationally important, but the SIV is usually not the best way to teach access, login, navigation, data entry, query response, sample shipment, image upload, or portal mechanics. Sites are typically sent separate vendor-required training, access instructions, certification requirements, quick-reference guides, or job aids.
Vendor training should be short, role-based, asynchronous where possible, and available just in time. Staff should not have to sit through an SIV walkthrough of a system they will still need to train on separately.
The SIV should address only the protocol-specific implications of the tools: which fields or workflows matter most for this study, where timing is critical, what errors could create deviations or missing data, and who should escalate what when something goes wrong.
Layer 3: Live SIV
The third layer is the live SIV. This should be reserved for protocol-specific content and discussion. The content may include the following areas:
- Study rationale
- Endpoints
- Eligibility
- Visit schedule
- Investigational product handling
- Dose modifications
- Prohibited medications
- Disease-specific assessments
- Unique safety risks
- Study-specific lab and imaging workflows
- Cohort or dose-escalation governance
- Sponsor/CRO-specific operational exceptions
This is where sponsor/CRO and site interaction is most valuable. It’s also where misunderstanding can create the greatest risk.
The model is not about less training. It is about better placement of training: reusable content delivered once, vendor mechanics covered asynchronously, and live SIV time reserved for protocol-specific risk.
What changes for sites
For sites, this model would reduce the experience of being retrained on the same fundamentals across every study. Staff would still need to demonstrate readiness, but the mechanism would be more efficient and more respectful of prior competency.
Role-based design also matters. A PI, coordinator, pharmacist, data manager, lab staff member, and imaging contact do not need identical training. A layered model makes it easier to assign the right content to the right people.
Sites could spend less time in generic slide review and more time preparing for the operational details unique to the trial.
What changes for sponsors and CROs
For sponsors and CROs, the benefits are better signal and better quality control.
When generic content is moved out of the SIV, the study team can focus on the decisions, risks, and workflows that matter most. The SIV becomes less of a compliance performance and more of a readiness conversation.
This also creates an opportunity for stronger quality control. Reusable modules can be reviewed, maintained, version-controlled, and improved over time. Vendor micro-modules can be tailored to role and task. SIV materials can be designed around protocol-specific risks instead of becoming a repository for every training item.
What changes for the industry
The larger opportunity is standardization.
A sponsor or CRO can make progress by creating its own reusable generic SIV module. That’s a helpful step. But if every sponsor or CRO creates a different version of the same generic content, the industry still perpetuates duplication.
A more ambitious model would allow common training elements to be owned, recognized, or accepted more broadly, reducing the need for experienced sites to repeat the same fundamentals sponsor by sponsor, CRO by CRO, and study by study.
That shift would require trust, governance, and alignment with regulatory expectations. But the data suggests the opportunity is real: The recurring content is identifiable, and the current model is not the only option.
Stay tuned for the full white paper
The Site-Sponsor Consortium’s upcoming white paper on site training will go deeper. It will address how to move from a good idea to a defensible operating model. The discussion will focus on several key topics:
- What evidence can be reused
- When training should still be assigned
- How decisions can be documented
- How a more streamlined SIV model can fit into broader efforts to reduce redundant site training
To help sponsors and CROs move from concept to implementation, the Site-Sponsor Consortium is developing an SIV Training Toolkit that includes practical tools for evaluating what belongs in reusable core training, vendor micro-training, live SIV discussion, or study-specific delta training.
And because SIVs are only one part of the larger site-training burden, the white paper will include a second implementation toolkit focused on another high-impact area of redundancy, as well as a roadmap for piloting these changes in practice. Release is expected in fall 2026.
